Skip to main content
main-content

Rheumatology

Latest articles

20-06-2017 | Rheumatology | News | Article

EULAR 2017

Reassuring findings on cancer risk in RA patients prescribed bDMARDs

 Findings from the ARTIS study group suggest that biologic disease-modifying antirheumatic drugs and tumor necrosis factor inhibitors are not associated with an increased overall cancer risk compared with conventional synthetic DMARDs.

19-06-2017 | Rheumatology | News | Article

EULAR 2017

Surprise findings for early high-dose glucocorticoids in RA treatment

The addition of high-dose glucocorticoids to first-line adalimumab and methotrexate in the treatment of rheumatoid arthritis fails to further improve efficacy, results of a phase IV study show.

17-06-2017 | Rheumatology | News | Article

EULAR 2017

Excess cardiovascular risk in RA patients may be on the decline

News in brief

Meta-analysis findings have confirmed an excess risk for cardiovascular events in patients with rheumatoid arthritis, but also show that this excess risk has declined since the year 2000.

17-06-2017 | Rheumatology | News | Article

EULAR 2017

Spondyloarthritis subtypes share comorbidities

Spondyloarthritis-related comorbidities are associated with ankylosing spondylitis, undifferentiated spondyloarthritis, and psoriatic arthritis subtypes of the disease, show study findings.

17-06-2017 | Rheumatology | News | Article

EULAR 2017

Fibromyalgia may contribute to RA disease remission failure

Fibromyalgia could contribute to patients with rheumatoid arthritis not reaching remission, concludes research presented at EULAR 2017.

17-06-2017 | Rheumatology | News | Article

EULAR 2017

Factors identified for predicting TNF inhibitor response in non-radiographic axSpA

Researchers have identified baseline predictors of clinical remission in patients with non-radiographic axial spondyloarthritis taking tumor necrosis factor inhibitors.

17-06-2017 | Rheumatology | News | Article

Sustained benefits of abatacept in PsA

The beneficial effects of abatacept treatment for patients with psoriatic arthritis are maintained for up to 1 year, suggest follow-up results of the ASTRAEA trial presented at EULAR 2017.

16-06-2017 | Rheumatology | News | Article

EULAR 2017

hs-cTnT associated with cardiovascular risk in SLE

News in brief

Study results suggest that  high-sensitivity cardiac troponin T could be a predictive biomarker of cardiovascular risk among patients with systemic lupus erythematosus.

16-06-2017 | Rheumatology | News | Article

EULAR 2017

SPIRIT-P2 results support ixekizumab for PsA patients with inadequate anti-TNF response

Phase III trial results presented at EULAR 2017 and published in The Lancet suggest that  ixekizumab is a promising treatment option for patients with psoriatic arthritis.

Source:

Lancet 2017; 389: 2317–2327

15-06-2017 | Rheumatology | News | Article

EULAR 2017

Potential biomarkers of pediatric lupus nephritis identified

Levels of three proteins in the urine are significantly elevated among children with lupus nephritis compared with controls, results of an interim analysis of a multicenter study suggest.

15-06-2017 | Rheumatology | News | Article

EULAR 2017

Comorbidities associated with poor treatment response in patients with PsA

News in brief

Psoriatic arthritis patients with comorbidities have higher disease activity and worse treatment response than those without comorbidities, study results presented EULAR 2017 suggest.

15-06-2017 | Rheumatology | News | Article

EULAR 2017

Early diagnostic tools for systemic sclerosis

Two studies presented at EULAR 2017 have highlighted new tools that could help diagnose systemic sclerosis in the early stages, supporting the EULAR campaign: “Don’t delay, Connect Today!”

14-06-2017 | Rheumatology | News | Article

EULAR 2017

Early intervention could reduce RA risk

Results of a systematic review and meta-analysis suggest that very early therapeutic intervention could reduce the risk for disease onset among patients with pre-rheumatoid arthritis.

12-06-2017 | Rheumatology | News | Article

‘Emotional support’ needed for RA patients making treatment decisions

News in brief

Study findings highlight the need to address negative feelings related to treatment decisions among patients with rheumatoid arthritis.

09-06-2017 | Rheumatology | News | Article

Equivalence of adalimumab biosimilar demonstrated in RA

Phase III trial results suggest that ABP 501 – the first US FDA-approved adalimumab biosimilar – has a similar efficacy, safety, and immunogenicity profile to its reference drug for the treatment of patients with moderate-to-severe rheumatoid arthritis.

Source:

Ann Rheum Dis 2017; Advance online publication

07-06-2017 | Rheumatology | News | Article

Teriparatide disappoints in RA trial

Treatment with teriparatide, a recombinant form of parathyroid hormone, does not reduce joint erosion among patients with rheumatoid arthritis undergoing treatment with tumor necrosis factor inhibitors, researchers report.

Source:

Arthritis Rheumatol 2017; Advance online publication

05-06-2017 | Rheumatology | Highlight | Article

Editor's pick

Chondroitin sulfate as good as celecoxib for knee OA

Results of a randomized trial suggest that pharmaceutical-grade chondroitin sulfate is as effective as the non-steroidal anti-inflammatory drug celecoxib for reducing pain and improving function among patients with symptomatic knee osteoarthritis.

Source:

Ann Rheum Dis 2017; Advance online publication

02-06-2017 | Rheumatology | News

Remote follow-up could be feasible for patients with RA

Results of a randomized trial suggest that rheumatoid arthritis patients with low disease activity who receive telephone-based follow-up achieve similar disease control to those receiving conventional outpatient follow-up.

Source:

Arthritis Care Res 2017; Advance online publication

31-05-2017 | Rheumatology | News | Article

Editor's pick

Higher fiber intake linked to lower symptomatic OA risk

An analysis of two US cohorts suggests that higher dietary fiber intake is associated with lower risk for symptomatic osteoarthritis.

Source:

Ann Rheum Dis 2017; Advance online publication

31-05-2017 | Rheumatology | News | Article

approvalsWatch

Sarilumab given FDA approval for RA

Click through to read more on this US FDA decision

image credits